The treatment of bipolar depression

Michael T. Compton, Charles Nemeroff

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: The treatment of bipolar depression represents a relatively understudied area in clinical psychiatry. The depressive phases of bipolar disorder can be very disabling, with significant associated comorbidity and suicide risk, impairment in functioning, and infringement on quality of life. We review the current evidence for the management of bipolar depression. Method: References for this review were obtained through MEDLINE searches of the medical literature on subjects pertaining to the treatment of bipolar depression. Search terms included bipolar depression, antidepressants, and bipolar disorder. Only publications in English are reviewed here. Results: Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder. Other mood stabilizers have demonstrated preliminary efficacy. Of the antidepressants, bupropion and the selective serotonin reuptake inhibitors may be associated with less risk of inducing hypomania, mania, and rapid cycling compared with tricyclic antidepressants. Monoamine oxidase inhibitors should be considered for patients with anergic bipolar depression. Electroconvulsive therapy has been shown to be highly efficacious. Other treatment modalities, including psychotherapy, sleep deprivation, phototherapy, and newer medications, require further research. Conclusions: Although the treatment of bipolar depression can be a complicated clinical task, the treatment armamentarium is expanding. Further research, especially in the form of randomized controlled trials, is warranted. Clinicians should be familiar with general guidelines for the use of psychopharmacologic agents for treating bipolar depression.

Original languageEnglish
Pages (from-to)57-67
Number of pages11
JournalJournal of Clinical Psychiatry
Volume61
Issue numberSUPPL. 9
StatePublished - Jul 25 2000
Externally publishedYes

Fingerprint

Bipolar Disorder
Therapeutics
Antidepressive Agents
Bupropion
Electroconvulsive Therapy
Monoamine Oxidase Inhibitors
Sleep Deprivation
Phototherapy
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Lithium
Research
MEDLINE
Psychotherapy
Suicide
Psychiatry
Publications
Comorbidity
Randomized Controlled Trials
Quality of Life

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The treatment of bipolar depression. / Compton, Michael T.; Nemeroff, Charles.

In: Journal of Clinical Psychiatry, Vol. 61, No. SUPPL. 9, 25.07.2000, p. 57-67.

Research output: Contribution to journalArticle

Compton, MT & Nemeroff, C 2000, 'The treatment of bipolar depression', Journal of Clinical Psychiatry, vol. 61, no. SUPPL. 9, pp. 57-67.
Compton, Michael T. ; Nemeroff, Charles. / The treatment of bipolar depression. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. SUPPL. 9. pp. 57-67.
@article{5461219645f4400d98ef1aa234d8349f,
title = "The treatment of bipolar depression",
abstract = "Background: The treatment of bipolar depression represents a relatively understudied area in clinical psychiatry. The depressive phases of bipolar disorder can be very disabling, with significant associated comorbidity and suicide risk, impairment in functioning, and infringement on quality of life. We review the current evidence for the management of bipolar depression. Method: References for this review were obtained through MEDLINE searches of the medical literature on subjects pertaining to the treatment of bipolar depression. Search terms included bipolar depression, antidepressants, and bipolar disorder. Only publications in English are reviewed here. Results: Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder. Other mood stabilizers have demonstrated preliminary efficacy. Of the antidepressants, bupropion and the selective serotonin reuptake inhibitors may be associated with less risk of inducing hypomania, mania, and rapid cycling compared with tricyclic antidepressants. Monoamine oxidase inhibitors should be considered for patients with anergic bipolar depression. Electroconvulsive therapy has been shown to be highly efficacious. Other treatment modalities, including psychotherapy, sleep deprivation, phototherapy, and newer medications, require further research. Conclusions: Although the treatment of bipolar depression can be a complicated clinical task, the treatment armamentarium is expanding. Further research, especially in the form of randomized controlled trials, is warranted. Clinicians should be familiar with general guidelines for the use of psychopharmacologic agents for treating bipolar depression.",
author = "Compton, {Michael T.} and Charles Nemeroff",
year = "2000",
month = "7",
day = "25",
language = "English",
volume = "61",
pages = "57--67",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 9",

}

TY - JOUR

T1 - The treatment of bipolar depression

AU - Compton, Michael T.

AU - Nemeroff, Charles

PY - 2000/7/25

Y1 - 2000/7/25

N2 - Background: The treatment of bipolar depression represents a relatively understudied area in clinical psychiatry. The depressive phases of bipolar disorder can be very disabling, with significant associated comorbidity and suicide risk, impairment in functioning, and infringement on quality of life. We review the current evidence for the management of bipolar depression. Method: References for this review were obtained through MEDLINE searches of the medical literature on subjects pertaining to the treatment of bipolar depression. Search terms included bipolar depression, antidepressants, and bipolar disorder. Only publications in English are reviewed here. Results: Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder. Other mood stabilizers have demonstrated preliminary efficacy. Of the antidepressants, bupropion and the selective serotonin reuptake inhibitors may be associated with less risk of inducing hypomania, mania, and rapid cycling compared with tricyclic antidepressants. Monoamine oxidase inhibitors should be considered for patients with anergic bipolar depression. Electroconvulsive therapy has been shown to be highly efficacious. Other treatment modalities, including psychotherapy, sleep deprivation, phototherapy, and newer medications, require further research. Conclusions: Although the treatment of bipolar depression can be a complicated clinical task, the treatment armamentarium is expanding. Further research, especially in the form of randomized controlled trials, is warranted. Clinicians should be familiar with general guidelines for the use of psychopharmacologic agents for treating bipolar depression.

AB - Background: The treatment of bipolar depression represents a relatively understudied area in clinical psychiatry. The depressive phases of bipolar disorder can be very disabling, with significant associated comorbidity and suicide risk, impairment in functioning, and infringement on quality of life. We review the current evidence for the management of bipolar depression. Method: References for this review were obtained through MEDLINE searches of the medical literature on subjects pertaining to the treatment of bipolar depression. Search terms included bipolar depression, antidepressants, and bipolar disorder. Only publications in English are reviewed here. Results: Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder. Other mood stabilizers have demonstrated preliminary efficacy. Of the antidepressants, bupropion and the selective serotonin reuptake inhibitors may be associated with less risk of inducing hypomania, mania, and rapid cycling compared with tricyclic antidepressants. Monoamine oxidase inhibitors should be considered for patients with anergic bipolar depression. Electroconvulsive therapy has been shown to be highly efficacious. Other treatment modalities, including psychotherapy, sleep deprivation, phototherapy, and newer medications, require further research. Conclusions: Although the treatment of bipolar depression can be a complicated clinical task, the treatment armamentarium is expanding. Further research, especially in the form of randomized controlled trials, is warranted. Clinicians should be familiar with general guidelines for the use of psychopharmacologic agents for treating bipolar depression.

UR - http://www.scopus.com/inward/record.url?scp=0033922785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033922785&partnerID=8YFLogxK

M3 - Article

C2 - 10826663

AN - SCOPUS:0033922785

VL - 61

SP - 57

EP - 67

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 9

ER -